Compare › Adlyxin vs Soliqua
Adlyxin vs Soliqua
Adlyxin and Soliqua are the same molecule — lixisenatide. They are sold under separate FDA applications (BLA208471 and BLA208673), which is why they carry different approved indications, different labels and different supply records. On the regulatory record they are distinct products with an identical active ingredient.
| Adlyxin | Soliqua | |
|---|---|---|
| Active ingredient | lixisenatide | lixisenatide |
| FDA application | BLA208471 | BLA208673 |
| First FDA action | 2016-07-27 | 2016-11-21 |
| Sponsor | Sanofi | Sanofi |
| EU authorisation | Not under this name | Not under this name |
| FDA supply status | No open records | No open records |
| FDA actions on file | 7 | 12 |
| Active trials of the molecule | 4 | 4 |
Everything above is a field from Drugs@FDA, the FDA Drug Shortage Database, the EMA register or ClinicalTrials.gov. There is no efficacy comparison here and there will not be one: head-to-head claims belong to the trials that made them, and which drug suits a particular person is a question for a clinician.
Full records: Adlyxin · Soliqua · lixisenatide